500200-53-3Relevant academic research and scientific papers
Palladium-catalyzed amination of chloro-substituted 5-nitropyrimidines with amines
Liu, Meng-Meng,Mei, Qiong,Zhang, Yi-Xiao,Bai, Peng,Guo, Xiang-Hai
, p. 583 - 587 (2017)
A concise and efficient approach was developed for the synthesis of mono-substituted and di-substituted pyrimidines products via palladium-catalyzed amination of chloro-substituted 5-nitropyrimidines and amines. This synthetic methodology can produce vari
Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors
Yu, Xu-Ri,Tang, Yun,Wang, Wen-Jing,Ji, Sen,Ma, Shuang,Zhong, Lei,Zhang, Chun-Hui,Yang, Jiao,Wu, Xiao-Ai,Fu, Zheng-Yan,Li, Lin-Li,Yang, Sheng-Yong
, p. 5449 - 5453 (2015)
Despite a potential application of PRMT1 inhibitors in cancer treatment, very few of PRMT1 inhibitors have been reported. To obtain novel potent PRMT1 inhibitors, structure optimizations towards a hit compound, 4-((6-chloro-5-nitropyrimidin-4-yl)amino)ben
Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
-
Page/Page column 90, (2008/06/13)
The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5-d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said compounds and the use thereof in drugs for the treatment of NAD(P)H oxidases-related diseases and disorders and inhibition of platelet activation.
